

Exhibit 2
ARIAD Pharmaceuticals, Inc.
Income Statement
(dollars in millions)

| | 2011 FY:11A | 2012 FY:12A | 2013 | | | | FY:13E | 2014 FY:14E | 2015 FY:15E |
|--|--------------------|--------------------|-------------------|-------------------|-------------------|-------------------|--------------------|--------------------|-------------------|
| | | | Q1A | Q2A | Q3A | Q4E | | | |
| Revenues | | | | | | | | | |
| Iclusig - U.S. revenue | \$0 | \$0 | \$6,400 | \$13,934 | \$16,658 | \$5,380 | \$42,372 | \$65,689 | \$158,277 |
| Iclusig - EU revenue | - | - | - | - | - | 1,329 | 1,329 | 42,854 | 54,345 |
| AP26113 - U.S. revenue | - | - | - | - | - | - | - | - | - |
| AP26113 - EU revenue | - | - | - | - | - | - | - | - | - |
| Royalties | - | - | - | - | - | - | - | - | - |
| License and collaboration revenue | 25,189 | 490 | 64 | 77 | 74 | 64 | 279 | 250 | 173 |
| Service revenue | 111 | 68 | - | - | - | - | - | - | - |
| Total Revenues | 25,300 | 558 | 6,464 | 14,011 | 16,732 | 6,773 | 43,980 | 108,793 | 212,796 |
| Expenses | | | | | | | | | |
| COGS | - | - | 269 | 228 | 415 | 335 | 1,247 | 5,195 | 10,303 |
| R&D expense | 77,743 | 144,710 | 41,263 | 40,668 | 45,145 | 47,402 | 174,478 | 140,685 | 133,337 |
| SG&A expense | 24,380 | 60,909 | 29,481 | 42,101 | 37,395 | 40,761 | 149,738 | 106,159 | 87,787 |
| Total Operating Expenses | 102,123 | 205,619 | 71,013 | 82,997 | 82,955 | 88,498 | 325,463 | 252,040 | 231,427 |
| Operating income | (76,823) | (205,061) | (64,549) | (68,986) | (66,223) | (81,726) | (281,484) | (143,247) | (18,632) |
| Interest income/(expense) | (65) | 113 | (62) | 87 | (6) | (6) | 13 | (24) | (24) |
| Revaluation of warrant liability | (46,715) | (15,924) | - | - | - | - | - | - | - |
| Pretax income/(loss) | (123,603) | (220,872) | (64,611) | (68,899) | (66,229) | (81,732) | (281,471) | (143,271) | (18,656) |
| Provision for income taxes/(income) | - | - | 59 | 86 | 110 | 113 | 368 | 1,197 | 2,174 |
| Net Income/(Loss) | (\$123,603) | (\$220,872) | (\$64,670) | (\$68,985) | (\$66,339) | (\$81,844) | (\$281,838) | (\$144,468) | (\$20,829) |
| GAAP EPS, basic | (\$0.93) | (\$1.34) | (\$0.36) | (\$0.37) | (\$0.36) | (\$0.44) | (\$1.54) | (\$0.78) | (\$0.11) |
| Weighted average shares outstanding, basic | 132,375 | 164,955 | 178,541 | 184,726 | 185,238 | 185,338 | 183,461 | 185,588 | 188,773 |

Sources: Company reports and William Blair & Company, L.L.C. estimates